Tocilizumab in Cardiac Transplantation

Phase 2 Completed 385 enrolled National Institute of Allergy and Infectious Diseases (NIAID) PPD Development, LP · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant. Specifically, the investigators will evaluate whether taking tocilizumab leads to less rejection, less development of unwanted antibodies, and better heart function.

Timeline

Start: 2018-12-20
Primary completion: 2025-03-25
Completion: 2025-03-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tocilizumab	Monoclonal antibody	8 mg/kg	Intravenous
Background	Methylprednisolone	Other / unclassified	—	—
Background	Mycophenolate Mofetil	Small molecule	—	—
Background	Mycophenolate Sodium	Unknown	—	—
Background	Prednisone	Other / unclassified	—	—
Background	Tacrolimus	Small molecule	—	Other

Indications

No indication recorded.